Cerebyx is a parenteral phenytoin therapy indicated for the control of generalized convulsive status epilepticus, the prevention and treatment of seizures occurring during neurosurgery and as a short-term substitute for oral phenytoin.
WASHINGTON, DC -- Jan. 29, 1999 -- Parke-Davis will be revising the vial and carton labels of its drug Cerebryx (fosphenytoin sodium injection) in response to serious adverse events, including death, associated with massive overdoses of the drug.
Fosphenytoin (Cerebyx®) One of the most common adverse effects unique to fosphenytoin is pruritus, of which the mechanism has not been fully elucidated. In the product labeling for fosphenytoin, pruritus occurs in 49% of patients who receive fosphenytoin compared to 5% of patients who receive phenytoin.1 Furthermore, higher infusion rates of fosphenytoin are associated with an increase in the incidence of adverse effects.